Professor of Pediatrics, University Tex Houston
Pediatrics
Dr. Eugenie S. Kleinerman, MD
|
|
Give Review
Doctor Eugenie S. Kleinerman, MD practices Pediatrics. She researched medicine at Duke University School of Medicine. Duke University School of Medicine is one of the top medical schools in the US. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. She received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Fellow (FAAP)". Eugenie Kleinerman is a published doctor as well. She has 100 publications published. The latest was: Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
Publications
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.
- Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.
- EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
- Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells.
- Blocking SDF-1alpha/CXCR4 downregulates PDGF-B and inhibits bone marrow derived pericyte differentiation and tumor vascular expansion in Ewing's tumors.
- Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.
- Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
- Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
- The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Me...
- Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression.
- MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.
- miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
- Genetically modified T cells targeting interleukin-11 receptor ?-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metasta...
- SDF-1{alpha} induces PDGF- B expression and the differentiation of bone marrow cells into pericytes.
- CAPER-? alternative splicing regulates the expression of vascular endothelial growth factor(165) in ewing sarcoma cells.
- Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosa...
- Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation.
- Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.
- Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual ...
- Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
- Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a repor...
- Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
- Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma.
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.
- Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors.
- Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation.
- VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL.
- The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
- Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
- Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
- COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
- Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels.
- Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis.
- The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells.
- VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
- Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients.
- VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
- Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-co...
- Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
- Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
- Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemci...
- EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins.
- Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma.
- Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
- Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
- Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.
- Fas expression in lung metastasis from osteosarcoma patients.
- Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
- Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
- E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
- A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
- Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
- Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro an...
- Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma.
- Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
- Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway.
- E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model.
- Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases.
- Alpha 4 integrin increases anoikis of human osteosarcoma cells.
- Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes.
- Nude mouse lung metastases models of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies.
- Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo.
- Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases.
- CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.
- Neisseria lactamica meningitis.
- Human recombinant macrophage colony stimulating factor activates murine Kupffer cells to a cytotoxic state.
- Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy.
- Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro.
- Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
- Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
- A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
- Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
- ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity.
- Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide.
- Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
- Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
- Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
- Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
- Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metasta...
- Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity.
- Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
- Osteosarcoma metastatic to the pancreas in young patients.
- Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
- Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills wit...
- Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic.
- Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
- Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26.
- Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-tra...
- Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
- Effect of Adriamycin on liposomal muramyl tripeptide''s ability to up-regulate monocyte cytokine expression.
- Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in huma...
- Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
- Liposomal MTP-PE.
- Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
- Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylet...
- Administration of liposomal MTP-PE by the local physician: the role of the research nurse.
- Liposomal MTP-PE: a promising new biologic response modifier.
- Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Schools
Duke University
Chldns Hospital National Med Center
National Cancer Institute
Doctors Specialties
- Pediatrics
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FAAP)
Education
-
Children's National Medical Center - George Washington University -
Duke University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Similar Doctors
|
|
Dr. Penelope T. Louis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Padma Swamy, MD |
|
|
Dr. Erynn M. Bergner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jill E. Sanders, MD |
|
|
Dr. Amrita Narang, MD |
|
|
Dr. Natalie Villafranco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Hotez, MD |
|
|
Dr. Kristen H. Arredondo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leon Freedman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Domalapalli M. Kumar, DO |
|
Dr. Barry L. Zietz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abel J. Paredes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria D. Alva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra R. Cohan, MD
This Doctor is OpenDoctor Recommended.
|